Moog F, Bangerter M, Diederichs C G, Guhlmann A, Kotzerke J, Merkle E, Kolokythas O, Herrmann F, Reske S N
Department of Nuclear Medicine, University of Ulm, Germany.
Radiology. 1997 Jun;203(3):795-800. doi: 10.1148/radiology.203.3.9169707.
To compare 2-deoxy-2-[fluorine-18]fluoro-D-glucose (FDG) positron emission tomography (PET) with computed tomography (CT) in primary nodal staging of malignant lymphoma.
Sixty consecutive patients with untreated, histopathologically proved malignant lymphoma (aged 7-72 years; 33 with non-Hodgkin lymphoma, 27 with Hodgkin disease) underwent FDG PET and contrast material-enhanced CT for nodal staging. Lymph node regions identified at both CT and PET were regarded as actual locations of disease. Discordant results were verified with biopsy or clinical follow-up whenever possible.
One hundred sixty of 740 evaluated lymph node regions were identified as diseased at both CT and PET. Of the 25 additional regions seen with PET, seven were true-positive; two, false-positive; and 16, unresolved. CT showed six additional disease manifestations; three were false-positive, and three were unresolved. Staging was changed in the four patients with the seven confirmed additional PET findings: from stage I to II in one patient and from stage II to III in three patients. Staging was changed from stage II to I in one of the three patients with false-positive CT findings.
FDG PET may be more accurate for detecting nodal lymphoma than incremental CT.
比较2-脱氧-2-[氟-18]氟-D-葡萄糖（FDG）正电子发射断层扫描（PET）与计算机断层扫描（CT）在恶性淋巴瘤原发淋巴结分期中的应用。
连续60例未经治疗、经组织病理学证实为恶性淋巴瘤的患者（年龄7 - 72岁；33例为非霍奇金淋巴瘤，27例为霍奇金病）接受FDG PET和对比剂增强CT检查以进行淋巴结分期。CT和PET均确定的淋巴结区域被视为疾病的实际位置。只要有可能就通过活检或临床随访来验证不一致的结果。
在740个评估的淋巴结区域中，有160个在CT和PET上均被确定为病变区域。在PET上发现的另外25个区域中，7个为真阳性；2个为假阳性；16个无法确定。CT显示另外6个疾病表现；3个为假阳性，3个无法确定。在有7个经证实的PET额外发现的4例患者中，分期发生了改变：1例患者从I期变为II期，3例患者从II期变为III期。在3例CT假阳性发现的患者中，有1例患者的分期从II期变为I期。
FDG PET在检测淋巴结淋巴瘤方面可能比增强CT更准确。
